Pharmaceutical News

RSS

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).

13 Jun 2013

Oklahoma tornado victims to receive nutritional support from Wellesse Premium Liquid Supplements

Americans affected by devastating Oklahoma tornadoes will receive nutritional support from Wellesse Premium Liquid Supplements. Wellesse has shipped 7,800 bottles of WELLESSE Liquid Multivitamin valued at over $77,000 to aid the victims of the Oklahoma Tornadoes.

13 Jun 2013

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

13 Jun 2013

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

New PSUMMIT 2 data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).

13 Jun 2013

Combination of Pressure Right and antiemetic drug therapy can reduce PONV with no adverse effects

From a clinical-based perspective, postoperative nausea and vomiting (PONV) can be characterized as an unmet global phenomenon in which anesthesia practitioners and PACU nurses worldwide are seeking more efficient clinical strategies for preventing PONV.

13 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma.

13 Jun 2013

Study reveals 83% of teens have unsupervised access to prescription medications

A new study in the Journal of Adolescent Health found that 83.4 percent of teens had unsupervised access to their prescription medications at home including 73.7 percent taking pain relief, anti-anxiety, stimulant and sedative medications that have the potential for abuse.

13 Jun 2013

First Edition: June 13, 2013

Today's headlines include reports about how employers are preparing for some parts of the health law to kick in.

13 Jun 2013

WHO issues interim policy guidance on inclusion of bedaquiline to treat adults with MDR-TB

WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far more expensive than those used to treat drug-susceptible TB.

13 Jun 2013

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced the launch of Constella® (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C,(1) in Europe. Constella® is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Viewpoints: Administration 'finally' comes around on Plan B; 'Legal loophole' creates another compounded drug scare

Reluctantly yielding to a federal-court decision, the Obama administration announced on Monday that it will take steps to allow a version of the so-called morning-after pill, known as Plan B One-Step, to be sold over the counter to girls and women of all ages. They will not need a prescription, nor will they be required to show any identification to obtain the emergency contraceptive. There will be no restrictions on where the drug can be sold; it will be up to the manufacturer to propose appropriate venues (6/11).

13 Jun 2013

Green coffee bean dietary supplements does not prevent weight gain in obese mice: Study

A major ingredient in those green coffee bean dietary supplements - often touted as "miracle" weight-loss products - doesn't prevent weight gain in obese laboratory mice fed a high-fat diet when given at higher doses.

13 Jun 2013

Common medications reduce brain plaques in mice

Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer's disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One.

13 Jun 2013

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event is taking over-the-counter non-steroidal anti-inflammatory drugs, often to treat a musculoskeletal complaint.

13 Jun 2013

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis.

13 Jun 2013

NeuroVive signs agreement with Isomerase Therapeutics to develop and commercialize cyclophilin-inhibiting molecules

NeuroVive Pharmaceutical AB (publ) (STO:NVP), a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from Biotica.

12 Jun 2013

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

UK and Australian scientists have been able to show ways in which we can markedly improve drug targeting of solid tumours, using tiny 'biosensors' along with new advanced imaging techniques.

12 Jun 2013

Background mortality rates can be used to communicate vaccine safety risks

In a study using the Vaccine Safety Datalink (VSD), investigators analyzed four years of data and determined that background mortality rates (rates of death irrespective of cause) are crucial in interpreting the numbers of deaths following vaccination.

12 Jun 2013

Pharmaceutical News

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

Oklahoma tornado victims to receive nutritional support from Wellesse Premium Liquid Supplements

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Combination of Pressure Right and antiemetic drug therapy can reduce PONV with no adverse effects

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Study reveals 83% of teens have unsupervised access to prescription medications

First Edition: June 13, 2013

WHO issues interim policy guidance on inclusion of bedaquiline to treat adults with MDR-TB

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Viewpoints: Administration 'finally' comes around on Plan B; 'Legal loophole' creates another compounded drug scare

Green coffee bean dietary supplements does not prevent weight gain in obese mice: Study

Common medications reduce brain plaques in mice

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

NeuroVive signs agreement with Isomerase Therapeutics to develop and commercialize cyclophilin-inhibiting molecules

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

Background mortality rates can be used to communicate vaccine safety risks

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News